Supporting Patients and Families Every Step of the Way
We are here to provide clear information, compassionate support, and access to innovative therapies for rare and complex diseases.
Support for Patients and Families
This page is designed for families who want clear, respectful information about Hurler syndrome (MPS I-H), current care, and how to find trusted support. We also offer a Dawn Therapeutics Patient and Family Information Pack to help you organise appointments, questions, and next steps.
Dawn Therapeutics is a preclinical company. We do not have clinical trials open at the moment. This page is for education and support, and does not replace advice from your child’s specialist team.
At a glance
- ✓Hurler syndrome is the severe form of MPS I and affects multiple organs over time.
- ✓Early diagnosis matters because treatment planning is time-sensitive.
- ✓Current care is built around HSCT, ERT, and long-term supportive multidisciplinary care.
- ✓Families often need support for hospital care, education, mobility, and mental wellbeing.
What this page can help with
- ✓Understanding the condition in simple language
- ✓Knowing what questions to ask your care team
- ✓Finding trusted resources for families
- ✓Requesting a free information pack from Dawn
Understanding Hurler syndrome in simple terms
Hurler syndrome, also called MPS I-H, is a rare inherited condition. Children with Hurler syndrome have very low or absent activity of an enzyme called alpha-L-iduronidase (IDUA). Without enough IDUA, natural substances called glycosaminoglycans (GAGs) build up inside cells and gradually affect many parts of the body, including the bones, heart, lungs, and brain.
Cause
IDUA enzyme deficiency due to changes in the IDUA gene.
Inheritance
Inherited in an autosomal recessive pattern.
Pattern
Progressive condition that affects multiple organ systems.
Early signs that often lead to diagnosis
Symptoms usually start in infancy and may become more obvious over the first few years of life. Families often notice a pattern rather than one single symptom.
Infancy
Hernias, frequent infections, mild developmental delay, and early facial changes.
Toddler years
Joint stiffness, reduced mobility, enlarged abdomen, snoring or noisy breathing.
Why timing matters
Early referral helps the specialist team plan treatment more quickly.
What usually happens after suspicion or screening
If Hurler syndrome is suspected, or if newborn screening is positive for MPS I, families are usually referred urgently for confirmatory testing and specialist review. A positive newborn screening result is not a diagnosis by itself, and more tests are needed.
Confirmatory tests
IDUA enzyme testing, urine GAGs, and IDUA gene analysis are commonly used to confirm the diagnosis.
Metabolic specialist referral
A specialist metabolic team coordinates assessment and helps explain the diagnosis and treatment pathway.
Treatment planning
The team discusses treatment timing, transplant suitability, enzyme therapy, and urgent supportive care needs.
Family support and care coordination
Families are usually supported through hospital visits, practical planning, and links to trusted support organisations.
Questions you can ask your specialist team
It is completely normal to feel overwhelmed. Bringing a written list of questions can help during appointments.
Diagnosis and severity
What tests confirmed the diagnosis, and what do they show about severity and urgency?
Treatment options now
Is HSCT being considered, is ERT needed now, and what is the expected timeline?
Specialist monitoring
Which specialists will be involved (heart, lungs, orthopaedics, ENT, hearing, eyes, dental, neurodevelopment)?
Emergency plan
Who should we contact if breathing, surgery, anaesthesia, or sudden health issues arise?
The three pillars of current care
Current care for severe MPS I-H is built around three pillars: haematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT with laronidase), and long-term multidisciplinary supportive care. Families often need all three parts of the care system, even if one treatment is the main focus.
Stem cell transplant
HSCT aims to provide a long-term source of enzyme-producing cells and is a key disease-modifying treatment for many children with severe MPS I-H.
- Most time-sensitive part of the pathway
- Best outcomes when done early
- Can help protect brain function
- Does not fully remove long-term care needs
Enzyme replacement therapy
ERT with laronidase is given as regular intravenous infusions and can help many body organs and tissues by reducing GAG storage.
- Often used before transplant and in ongoing care
- Can improve many somatic symptoms
- Does not adequately treat the brain
- Works as part of a wider care plan
Multidisciplinary long-term care
Because Hurler syndrome affects many organs, supportive care remains essential before and after HSCT or ERT.
- Heart, lung, airway, hearing and vision care
- Orthopaedic and mobility support
- Dental, nutrition and growth support
- Developmental and school planning
Support for everyday life
Hurler syndrome affects the whole family. Alongside hospital care, many families need help with education, practical routines, emotional support, and coordination between different teams. Building a support network can reduce isolation and make day to day life more manageable.
Hospital and appointments
Ask for a named point of contact, keep appointment notes, and bring a written question list each time.
Education and school planning
Early school support planning can help with learning, mobility, communication, and attendance around treatment.
Mental health and family wellbeing
Parents, siblings, and carers may all need emotional support. Peer groups and counselling can help.
Speech, hearing, and vision
Regular reviews can support communication, learning, and social confidence over time.
Mobility and daily adaptations
Joint stiffness and skeletal issues can affect comfort and independence, so practical adaptations matter.
Transition and long-term planning
As children grow, families may need support planning for adult services and long-term follow-up.
Is a positive newborn screening result the same as a diagnosis? +
Why does early diagnosis matter so much? +
Does treatment end after HSCT? +
Can Dawn Therapeutics offer treatment right now? +
What is the Dawn Patient and Family Information Pack? +
Request a free information pack
If you are a parent, family member, or carer, you can request a Dawn Patient and Family Information Pack. We can send a practical pack to help you organise information, prepare for appointments, and find trusted resources.
What is included in the pack
We can provide a simple, family-friendly pack to help you prepare for the next stage of care and find trusted information.
- ✓Plain-language overview of Hurler syndrome (MPS I-H)
- ✓Diagnosis and care pathway checklist for appointments
- ✓Questions to ask your specialist team
- ✓Overview of HSCT, ERT, and supportive care
- ✓Practical support and community signposting
- ✓Links to detailed resources on HurlerSyndrome.org
Useful pages from our sister site, HurlerSyndrome.org
For detailed educational content, visit HurlerSyndrome.org. It provides patient and family focused information on diagnosis, treatment, supportive care, and living with Hurler syndrome.
Dawn Therapeutics status
Dawn Therapeutics is a preclinical biotechnology company working on tissue-targeted delivery platforms and a lead programme in Hurler syndrome. We do not have a clinical trial open at this time, but we are committed to sharing clear educational information and supporting respectful communication with families.
Partner, clinician, or charity contact
If you are a clinician, patient charity, or support organisation and would like to collaborate on family education materials, you can use the same request form above and select your role in the form.
Our Promise

Transparency
We will always keep you informed about progress, risks, and benefits.

Compassion
Your voice matters in our decision-making.

Access
We aim to make our therapies available globally, not just in select markets.